Relmada Therapeutics Investor Relations Material
Latest events
Q1 2025
Relmada Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Relmada Therapeutics Inc
Access all reports
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focusing on developing innovative treatments for central nervous system (CNS) diseases, with a particular emphasis on major depressive disorder. The company's flagship product, esmethadone (d-methadone, dextromethadone, REL-1017), is a novel N-methyl-D-aspartate (NMDA) receptor antagonist currently inclinical trials, aimed at serving as an adjunctive or monotherapy treatment for MDD in adults. The company is headquartered Coral Gables, Florida. Its shares are listed on the Nasdaq.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
RLMD
Country
🇺🇸 United States